The study found that the active ingredient in GLP-1 drugs "significantly improved" motivation in patients with major ...

Treatment with oral semaglutide (Rybelsus) significantly improved motivation measures in patients with major depressive ...

A study published in the Journal of Affective Disorders proposes a novel, fully automated artificial intelligence (AI) algorithm leveraging ExtraTrees (ET) forests to distinguish patients with major ...

Women with MDD who did not use antidepressants had more than twice the risk of breast cancer recurrence as women without MDD. Women with breast cancer who also have major depressive disorder (MDD) ...

Credit: Otsuka. At this time, the product is available to patients for a discounted price of $50; the full price is $200. Rejoyn ™, the first prescription digital therapeutic cleared for the treatment ...

Zachary Contreras of Sharp Health Plan discusses how predictive tools, artificial intelligence-driven analytics, and digital monitoring can help identify treatment-resistant depression early, enabling ...

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

The largest and most ethnically diverse study of its kind has identified 697 genetic variants linked to major depressive disorder (MDD). The research also highlights potential therapies for ...

Please provide your email address to receive an email when new articles are posted on . Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response to at ...

Definium Therapeutics (NASDAQ:DFTX) is approaching what Chief Executive Officer Rob Barrow described as an “incredibly ...